1	Bacterial Pneumonia and Respiratory Culture Utilization among Hospitalized Patients with and
2	without COVID-19 in New York City
3	
4	Maxwell D. Weidmann, MD, PhD ¹ , Gregory J. Berry, PhD ¹ , Jason E. Zucker, MD ² , Simian Huang ² ,
5	Magdalena E. Sobieszczyk, MD ² , and Daniel A. Green, MD ¹
6	
7	¹ Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY
8	² Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical
9	Center, New York, NY
10 11	Keywords: COVID-19, SARS-CoV-2, Pneumonia, Co-infection, Respiratory Culture
12	Running Title: Respiratory Culture COVID-19
13 14	#Address correspondence to:
15	Daniel A. Green, M.D., Ph.D.
16	Assistant Professor of Pathology & Cell Biology
17	Columbia University Irving Medical Center
18	3959 Broadway, CHC 3-324
19	New York, NY 10032
20	(212)-305-6301
21	dag2149@cumc.columbia.edu
22	
23	
24	

25

26 <u>Abstract</u>

27	COVID-19 is associated with prolonged hospitalization and a high risk of intubation, which raises
28	concern for bacterial co-infection and antimicrobial resistance. Previous research has shown a wide range
29	of bacterial pneumonia rates for COVID-19 patients in a variety of clinical and demographic settings, but
30	none have compared hospitalized COVID-19 patients to patients testing negative for SARS-CoV-2 in
31	similar care settings. We performed a retrospective cohort study on hospitalized patients with COVID-19
32	testing from 10 March 2020 to 31 December 2020. A total of 19,219 patients were included, of which
33	3,796 tested positive for SARS-CoV-2. We found a 2.6-fold increase ($p < 0.001$) in respiratory culture
34	ordering in COVID-19 patients. On a per-patient basis, COVID-19 patients were 1.5-fold more likely
35	than non-COVID patients to have abnormal respiratory cultures (46.8% vs. 30.9%, $p < 0.001$), which was
36	primarily driven by patients requiring intubation. Among patients with pneumonia, a significantly higher
37	proportion of COVID-19 patients had ventilator-associated pneumonia (VAP) relative to non-COVID
38	patients (85.7% vs 55.1%, p <0.001), but a lower proportion had community-acquired (12.2% vs 22.1%, p
39	< 0.01) or hospital-acquired pneumonia (2.1% vs. 22.8%, p < 0.001). There was also a significantly
40	higher proportion of respiratory cultures positive for MRSA, K. pneumoniae, and antibiotic-resistant
41	organisms in COVID-19 patients. Increased rates of respiratory culture ordering for COVID-19 patients
42	therefore appear to be clinically justified for patients requiring intubation, but further research is needed
43	to understand how SARS-CoV-2 increases the risk of VAP.
44	
45	
45	
46	

- 47
- 48

49

50 Introduction

71

51 Concern for bacterial co-infection among COVID-19 patients resulted in empirical antimicrobial 52 therapy given to a large proportion of patients hospitalized at our medical center during 2020 [1]. While a 53 relatively high rate of bacterial and influenza co-infection has characterized hospitalized influenza 54 patients, with estimates ranging from 11% to 35% [2, 3], less is known about the rate of bacterial 55 pneumonia in hospitalized COVID-19 patients. Further, in influenza, bacterial co-infection has been 56 found to be more frequently of community-origin, with one study of hospitalized adults in the US finding 57 that more than 54% of co-infections in adults were diagnosed within the first 48 hours of hospitalization 58 [3]. Several studies have examined bacterial co-infection for COVID-19 patients in inpatient and ICU 59 settings, generally finding lower rates than for influenza patients [4-7]. Of the two largest such studies, 60 one found very low rates of community-acquired pneumonia (CAP) (1.5%) [7], while the other found an 61 overall bacterial pneumonia rate of 2.1%, with the overwhelming majority being HAP or VAP [6, 8]. One 62 study among ICU patients found much higher rates of patients with abnormal respiratory cultures (28%), 63 however 90% of these patients required mechanical ventilation [9]. 64 Therefore, when all hospitalized patients are considered together, rates of bacterial pneumonia 65 appear lower in COVID-19 patients relative to hospitalized influenza patients, and in contrast to 66 influenza, few of these infections are community-acquired. However, none of these studies have assessed the concurrent rate of bacterial co-infections, including HAP and VAP rates, in patients testing negative 67 68 for SARS-CoV-2 during the same period. This lack of a direct comparison between COVID-19 and non-69 COVID-19 infected patients makes it difficult to determine whether the highly disparate reported rates of 70 bacterial co-infection represent the heterogeneity of the patient populations studied, or a truly elevated

Additionally, respiratory culture utilization among COVID-19 patients has not been previously
 studied. Understanding the rates of respiratory culture ordering and positivity among COVID-19 patients
 is needed to determine whether culture ordering is appropriate among hospitalized COVID-19 patients,

risk of bacterial pneumonia associated with SARS-CoV-2 infection.

75	and to understand the risk of HAP and VAP in this population. To study this further, we compared rates
76	of bacterial pneumonia, respiratory culture ordering, bacterial etiologies, and antibiotic resistance between
77	patients testing positive and negative for COVID-19 in the same hospital setting.

78 Materials and Methods

A retrospective cohort study was conducted on all hospitalized patients with SARS-CoV-2 testing
performed at Columbia University Irving Medical Center (CUIMC) located in New York City from 10
March 2020 to 31 December 2020. SARS-CoV-2 RT-PCR testing was performed in-house using the
following assays: Cobas SARS-CoV-2 (Roche Molecular Systems, Inc., Branchburg, NJ), Xpert Xpress
SARS-CoV-2 (Cepheid, Sunnyvale, CA), and a laboratory-developed test from the Wadsworth Center at
the New York State Department of Health.

Data were extracted from medical records to compare respiratory culture utilization and culture
results between COVID-19 and non-COVID patients; these data included time of SARS-CoV-2 testing,
SARS-CoV-2 test results, dates of admission and discharge, intubation status, number of respiratory
cultures performed, time of respiratory culture orders, and results of respiratory culture testing, including
time of culture results, bacterial species recovered, and antimicrobial susceptibility.

90 Rates of respiratory culture utilization and culture positivity were compared between COVID-19 and 91 non-COVID patients, as was the distribution of recovered species, antimicrobial susceptibility profiles, 92 intubation status and ordering time of positive cultures during hospital admission to stratify pneumonia 93 cases into community-acquired (≤ 2 days) vs. hospital-acquired (≥ 2 days) vs ventilator-associated (≥ 2 days after intubation) [8]. A positive respiratory culture was defined as any potential respiratory pathogen 94 95 recovered from culture, whereas a negative result was defined as either no growth, when cultures were 96 resulted as "mixed commensal microbiota," or when only yeast were isolated. Respiratory cultures were 97 excluded if SARS-CoV-2 testing was performed after respiratory cultures were ordered to ensure that all culture results analyzed were from patients of known COVID-19 status at time of testing. 98

99 Chi-squared testing was used to identify statistically significant differences in rates of respiratory 100 culture ordering, positivity, antibiotic resistance, and CAP, HAP or VAP in COVID-19 positive and 101 negative patients. A two-tailed Student's t-test was used to assess statistical significance in time to 102 respiratory culture positivity (when results of continuous variables were being compared). Data analysis 103 was initially performed using Microsoft Excel, with statistical tests performed using R and R-Studio for 104 reproducibility with scripts included in supplemental data.

- 105
- 106 <u>Results</u>

107 Demographics of SARS-CoV-2 positive and negative populations

A total of 19,275 participants were initially included; 3,805 (19,7%) tested positive for SARS-CoV-2 108 109 and 15,470 (80.3%) tested negative. 56 patients were excluded due to respiratory cultures ordered prior to 110 SARS-CoV-2 testing, leaving 19,219 participants for study analysis. SARS-CoV-2 positivity rates varied 111 widely over the study period, from a peak of nearly 60% in April 2020 to a low of just over 3% in 112 September 2020 (Supplemental Figure 1). Demographic characteristics of included patients are shown in **Table 1**. Compared to non-COVID patients, COVID-19 patients were older (p < p) 113 0.001), more likely to be male (p < 0.001), more likely to be Hispanic/Latino, less likely to be 114 white, and were more likely to receive care in the ICU (p < 0.001). The mortality rate was also 115 5.6-fold higher (16.9% vs. 3.0%, p < 0.001) and intubation rate 2.9-fold higher (16.6 vs. 5.7, p < 0.001) 116 117 0.001) for COVID-19 patients.

118

119 Increased rates of respiratory culture ordering in COVID-19 patients

COVID-19 patients were 2.6 times as likely to have respiratory cultures ordered compared to non COVID patients (16.0 % vs 6.2%, p < 0.001, Table 2). Although the rate of respiratory culture ordering
 varied by month (Figure 1A), significantly higher ordering was seen among COVID-19 patients across

125	Figure 1B).
124	per patient for COVID-19 patients relative to non-COVID patients (4.3 vs 2.7 per patient, p <0.001,
123	all months except July 2020. Increased ordering was also reflected in a higher number of cultures ordered

A much higher rate of respiratory culture ordering was seen overall among intubated patients
(57.5%) vs non-intubated patients (4.4%). Among intubated patients, however, ordering was still
significantly higher for those with COVID-19 compared to non-COVID patients (71.5% vs. 47.4%, p <
0.001, Table 2, Supplementary Figure 2). In addition, among patients who did not require intubation,
there was also a significantly higher rate of respiratory culture ordering for COVID-19 relative to nonCOVID patients (6.1 vs 4.1%, p < 0.001, Supplementary Figure 2D & Table 2).

132

133 Higher likelihood of respiratory culture positivity among intubated COVID-19 patients.

Overall, 7.6% of COVID-19 patients had positive respiratory cultures vs. 1.8% for non-COVID
patients (Figure 2, Table 3). Among patients who had respiratory cultures ordered, COVID-19 patients
were also more likely than non-COVID patients to have an abnormal culture (46.8% vs 30.9%, p <
0.001). Even accounting for the higher rate of respiratory culture ordering among COVID-19 patients, on
a per culture basis, COVID-19 patients still had a higher percentage of positive cultures (33.4% vs 26.9%,

139 p < 0.001, **Table 3**).

140 The higher rate of abnormal cultures among COVID-19 patients was primarily driven by patients requiring intubation. A total of 26.7% of all intubated patients had abnormal respiratory cultures collected 141 142 more than 48 hours after intubation, qualifying as ventilator-associated pneumonia (VAP). Amongst 143 intubated patients, VAP was more than twice as likely in COVID-19 patients relative to non-COVID 144 patients (39.0% vs. 17.9%, p < 0.001, Supplementary Figure 2E, Table 3). When looking at only 145 intubated patients who had respiratory cultures ordered, there remained a significantly higher proportion 146 of COVID-19 positive patients with VAP compared to non-COVID patients (62.0% vs. 51.5%, p < 0.01, Supplementary Figure 2E, Table 3) However, among non-intubated patients, there were no significant 147

148 differences by COVID-19 status in the proportion of patients with respiratory cultures ordered that 149 resulted as abnormal or the proportion of total patients with abnormal respiratory culture results 150 (Supplementary Figure 2E-F, Table 3). 151 Among culture-positive patients, COVID-19 patients had a significantly lower rate of CAP, defined 152 as abnormal cultures within the first two days of admission, compared to non-COVID patients (12.2% vs 22.1%, p < 0.01, Figure 3, Table 4). Conversely a significantly higher proportion of pneumonia cases 153 154 also occurred at least two days after admission for COVID-19 positive patients relative to non-COVID 155 patients (Figure 3), and this difference was particularly pronounced in patients with positive cultures at least 10 days after admission (64.8% vs. 42.1%, p < 0.001). When we looked specifically at HAP, defined 156 157 as abnormal respiratory cultures that resulted more than two days after admission but not in patients who had been ventilated for more than two days, we found a significantly lower rate among COVID-19 158 159 patients relative to non-COVID patients (2.1% vs. 22.8%, p < 0.001, Figure 3, Table 4). The 160 overwhelming majority (85.7%) of bacterial pneumonia cases among COVID-19 patients were ventilatorassociated, and this was significantly higher than the rate of VAP in non-COVID patients with bacterial 161 162 pneumonia (55.1%, p < 0.001, Figure 3, Table 4). 163 164 Bacterial etiologies of positive respiratory cultures 165 Respiratory cultures grew a wide range of bacterial pathogens in our patient population 166 (Supplementary Table 1). The most common organism overall was *P. aeruginosa* (Figure 4). For COVID-19 patients, the most common organisms in descending order were S. aureus, P. aeruginosa and 167 168 K. pneumonia. For non-COVID patients, the most common organisms in descending order were P. 169 aeruginosa, S. aureus and K. Pneumoniae (Figure 4). Among patients with abnormal respiratory cultures, 170 methicillin-resistant S. aureus infections (MRSA) were more common for COVID-19 patients (8.9% vs. 171 5.4%, p < 0.05, Figure 4), and there was a significant increase in the proportion of overall COVID-19

positive vs. negative patients with MRSA respiratory infections (1.05% vs. 0.15%, p < 0.001). There was

also a significantly higher proportion of COVID-19 patients whose cultures grew *K. pneumoniae* (26.1%)

- 174 vs. 16.3%, p < 0.01, **Figure 4**).
- 175

176 Antibiotic resistance in COVID-19 bacterial pneumonia

177 In agreement with our finding of increased rates of MRSA-positive respiratory cultures in COVID-

178 19 patients, we found increased rates of resistance to penicillin class antibiotics (penicillin, ampicillin,

179 oxacillin), 63.4 vs. 50.1% of COVID-19 positive vs. negative patients who had an abnormal culture result

180 (p < 0.05, **Supplemental Figure 3**). Rates of penicillin-class resistance amongst gram-positive organisms

181 were higher amongst COVID-19 patients (51.8 vs. 40.7%), but this difference was not significant.

182 Relative to non-COVID patients, COVID-19 patients showed no significant increases in rates of

- 183 Enterbacterales resistant to 3rd-generation cephalosporins, carbapenem-resistant Enterobacterales, and
- 184 carbapenem-resistant *P. aeruginosa or A. baumannii*.

185 Discussion

186 During the first 10 months of the COVID-19 pandemic we found significantly higher utilization of respiratory cultures for COVID-19 patients compared to non-COVID patients at our NYC medical center. 187 Yet despite the increased ordering, intubated COVID-19 patients still had a higher percentage of 188 189 abnormal respiratory cultures than intubated non-COVID patients, suggesting that COVID-19 patients 190 have an elevated risk for VAP. Bacterial pneumonia in COVID-19 patients was much more likely to be 191 ventilator-associated and less likely to be community acquired when compared to non-COVID patients. When excluding intubated patients, rates of hospital-acquired pneumonia were lower among COVID-19 192 relative to non-COVID patients. This study is the first to directly assess respiratory culture ordering and 193 194 positivity in COVID-19 and non-COVID patients in the same hospital. Given the higher rate of positivity 195 amongst intubated COVID-19 patients, respiratory culture ordering appears warranted for this subset of hospitalized COVID-19 patients in whom there is a higher suspicion for bacterial pneumonia. 196

197 While more than 80% of respiratory co-infections in COVID-19 patients occurred more than two 198 days into hospitalization, and the majority of these occurred well into hospitalization (> 10 days), nearly 199 all these cases qualified as VAP and were therefore attributable to intubation rather than other sources of 200 hospital-acquired infection. Only 0.7% of non-intubated COVID-19 patients were found to have bacterial 201 pneumonia, and when this was normalized to respiratory culture ordering, the rate was lower than that for 202 non-intubated non-COVID patients. We also found similarly low rates of CAP in COVID-19 patients 203 compared to what has previously been cited in the literature. A recent study of hospitalized COVID-19 204 patients looking specifically at rates of bacterial co-infection within the first three days of hospitalization 205 and finding 1.1% with probable infection, and additional 12.4% with possible co-infection, when all types 206 of infection were considered [10]. Looking specifically at respiratory bacterial co-infections, our study 207 found 1.2% of COVID-19 patients with positive cultures in the first three days of hospitalization, in 208 contrast to 6.3% of COVID-19 patients with abnormal cultures representing HAP or VAP by this 209 definition. The low rate of community-acquired respiratory infections we found here further supports 210 these authors' conclusions that empiric antibiotic therapy for COVID-19 patients is generally not 211 indicated during early hospitalization [10, 11]. Similarly, our finding that non-intubated patients had 212 lower rates of bacterial pneumonia, when those rates were normalized by respiratory culture ordering, 213 argues against routine respiratory culture and empiric pneumonia therapy in these patients. However, the 214 relatively high rates of VAP that we found in COVID-19 patients supports a low threshold for respiratory 215 culture ordering and initiation of antimicrobial therapy for intubated patients.

Abnormal respiratory cultures of COVID-19 patients were enriched for pathogens associated with hospital-acquired infection with a generally similar proportion non-COVID patients (**Figure 4**). However, there were significant increases in both *Klebsiella pneumoniae* and MRSA respiratory infections, which we interpreted as further corroborating an increased level of hospital-acquired infections for COVID-19 positive patients, particularly relative to the total number of patients testing positive. Overall rates of resistance to penicillin-class antibiotics were significantly higher in respiratory isolates from COVID-19

222 positive patients, which corroborates data from other studies demonstrating high rates of MRSA and 223 MDR bacterial infections in COVID-19 patients [6, 12]. One such study also showed that there were 224 significant increases in antibiotic resistance by the duration of hospital stay, including rates of MRSA, 225 vancomycin resistant Enterococcus (VRE), ceftriaxone-resistant Enterbacterales, carbapenem-resistant Enterobacterales and carbapenem-resistant P. aeruginosa or A. baumannii [12]. Interestingly, we did not 226 227 find significant increase in resistance rates between COVID-19 positive and negative patients for 228 ceftriaxone-resistant Enterbacterales, carbapenem-resistant Enterobacterales and carbapenem-resistant P. 229 aeruginosa or A. baumannii. However, further study is necessary to understand the mechanism by which 230 MRSA rates are increased by SARS-CoV-2 infection, and whether this is via direct effect of the virus on 231 the host environment or indirectly through affecting host exposure to drug resistant pathogens. 232 Some limitations of this study include its representation of data from a single institution only. There 233 were also significant baseline demographic differences in the COVID-19 positive and negative 234 populations. Inadequate SARS-CoV-2 testing capacity also makes results from March of 2020 difficult to interpret, as false negative rates may have been increased in this setting. Prior to March 23rd, 2020, not all 235 236 patients admitted to CUIMC were tested for SARS-CoV-2 due to limited capacity, and this population of 237 unknown COVID-19 status was not included in our data. The data available did not include sensitivities 238 for several antibiotic classes, such as fluoroquinolones, aminoglycosides and macrolides, that would have 239 been helpful in a more comprehensive characterization of resistance in our population of patients with 240 bacterial pneumonia. In addition, the data analyzed here represents one period early in the pandemic, 241 during which time rates of COVID-19 varied greatly in the population (Supplemental Figure 1). The 242 COVID-19 patient population represented here is largely composed of those infected during the initial surge of infections in NYC from March-May of 2020 and may not represent later stages of the pandemic 243 244 during which different SARS-CoV-2 variants have become dominant. 245 In summary, the data presented here suggests that COVID-19 infection resulted in higher rates of

bacterial co-infection relative to patients who tested negative during the same period, but that these

- 247 infections were seen in the setting of prolonged hospitalization and intubation, rather than increased rates
- of CAP as seen with other viruses such as influenza. Possible explanations for these findings include
- 249 longer periods of hospitalization for COVID-19 patients, inadequate infection control practices during
- acute phases of the pandemic, or direct effects of SARS-CoV-2 itself on the pathogenesis of bacterial
- 251 pneumonia during intubation. Based on these findings, respiratory culture ordering is indicated for
- 252 COVID-19 patients with prolonged hospitalization and ventilator dependence. However, further study is
- 253 necessary to understand why SARS-CoV-2 predisposes intubated patients to VAP.

254

255 <u>References</u>

256 Sepulveda, J., et al., Bacteremia and Blood Culture Utilization during COVID-19 Surge in New 1. York City. J Clin Microbiol, 2020. 58(8). 257 258 2. Klein, E.Y., et al., The frequency of influenza and bacterial coinfection: a systematic review and 259 meta-analysis. Influenza Other Respir Viruses, 2016. 10(5): p. 394-403. 260 3. Shah, N.S., et al., Bacterial and viral co-infections complicating severe influenza: Incidence and 261 impact among 507 U.S. patients, 2013-14. J Clin Virol, 2016. 80: p. 12-9. 262 4. Langford, B.J., et al., Bacterial co-infection and secondary infection in patients with COVID-19: a 263 living rapid review and meta-analysis. Clin Microbiol Infect, 2020. 26(12): p. 1622-1629. 264 5. Lansbury, L., et al., Co-infections in people with COVID-19: a systematic review and meta-265 analysis. J Infect, 2020. 81(2): p. 266-275. Nori, P., et al., Bacterial and fungal coinfections in COVID-19 patients hospitalized during the 266 6. 267 New York City pandemic surge. Infect Control Hosp Epidemiol, 2021. 42(1): p. 84-88. Vaughn, V.M., et al., Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in 268 7. 269 Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. 270 Clin Infect Dis, 2021. 72(10): p. e533-e541. 271 8. Kalil, A.C., et al., Management of Adults With Hospital-acquired and Ventilator-associated 272 Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and 273 the American Thoracic Society. Clin Infect Dis, 2016. 63(5): p. e61-e111. 274 9. Contou, D., et al., Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia 275 admitted to a French ICU. Ann Intensive Care, 2020. 10(1): p. 119. 276 10. Coenen, S., et al., Low frequency of community-acquired bacterial co-infection in patients 277 hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a 278 retrospective cohort study. Antimicrob Resist Infect Control, 2021. 10(1): p. 155. 279 Wang, L., et al., An observational cohort study of bacterial co-infection and implications for 11. 280 empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West 281 London. J Antimicrob Chemother, 2021. 76(3): p. 796-803. 282 Kubin, C.J., et al., Characterization of Bacterial and Fungal Infections in Hospitalized Patients 12. 283 With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. 284 Open Forum Infect Dis, 2021. 8(6): p. ofab201.

285 **Tables:**

Table 1: Demographics of SARS-CoV-2 Positive and Negative Patient Population.

<u>Category</u>	Sub-Category	SARS-CoV-2 Positive	SARS-CoV-2 Negative	p-value
Age (years)	<u>Mean (±SD)</u>	62.0 ± 21.0	48.7 ± 26.4	p < 1e-15
Sex	<u>Male</u>	54.0%	43.2%	p < 1e-15
	<u>Female</u>	46.0%	56.8%	
Race	<u>White</u>	11.8%	19.0%	p < 1e-15
	<u>Black</u>	12.8%	13.1%	
	Hispanic/Latino	51.9%	39.6%	
	<u>Other</u>	23.5%	28.3%	
Care Setting	<u>ED</u>	<0.1%	<0.1%	p < 0.00001
	<u>Admitted</u>	79.9%	83.1%	
	<u>ICU</u>	20.0%	16.9%	
Mortality		16.9%	3.0%	p < 1e-15
Intubation		16.6%	5.7%	p < 1e-15

287

288 Table 2: Respiratory Culture Ordering

<u>Metric</u>	Total	SARS-CoV-2 Positive	SARS-CoV-2 Negative	p-value
Total Patients	19219	3796	15423	
Total cultures ordered	5152	2587	2565	
Patients with respiratory cultures ordered	1569 (8.2%)	607 (16.0%)	962 (6.2%)	p < 1e-15
Cultures ordered per patient	3.3	4.3	2.7	p < 1e-14
Intubated patients with respiratory cultures ordered	867 (57.5%)	451 (71.5%)	416 (47.4%)	p < 1e-15
Non-intubated patients with respiratory cultures ordered	792 (4.4%)	195 (6.1%)	597 (4.1%)	p < 1e-5

289 Table 3: Respiratory Culture Positivity

<u>Metric</u>	Total	SARS-CoV-2 Positive	SARS-CoV-2 Negative	p-value
Total Patients	19219	3796	15423	
Intubated Patients	1509 (7.9%)	631 (16.6%)	878 (5.7%)	
Patients who had abnormal respiratory cultures	572 (3.0%)	287 (7.6%)	285 (1.8%)	p < 1e-15
% of patients with abnormal cultures among patients with cultures ordered	37.0%	46.8%	30.9%	p < 1e-9
Cultures that resulted as abnormal	1554 (30.2%)	863 (33.4%)	691 (26.9%)	р < 1е-б
Intubated patients with Ventilator- associated pneumonia (VAP) (%)	403 (26.7%)	246 (39.0%)	157 (17.9%)	p < 1e-15
% of intubated patients with respiratory cultures ordered and Ventilator-associated pneumonia (VAP)	57.4%	62.0%	51.5%	p < 0.01
Non-intubated patients who had abnormal respiratory cultures (%)	133 (0.7%)	24 (0.7%)	109 (0.7%)	p = 1
% of non-intubated patients with respiratory cultures ordered that resulted as abnormal	16.8%	12.3%	18.3%	p = 0.069

290

291 **Table 4: Bacterial Pneumonia Categories**

<u>Metric</u>	Total	SARS-CoV-2 Positive	SARS-CoV-2 Negative	p-value
Total Pneumonia Patients	572	287	285	
Cases of CAP	98 (17.1%)	35 (12.2%)	63 (22.1%)	p < 0.01
Cases of HAP	71 (12.4%)	6 (2.1%)	65 (22.8%)	p < 1e-12
Cases of VAP	403 (70.4%)	246 (85.7%)	157 (55.1%)	p < 1e-14

293 Figure Legends:

294 Figure 1: Respiratory culture ordering by COVID-19 status

- A) Percentage of patients with respiratory cultures ordered, by month and total. B) Average number of
- respiratory cultures ordered per patient. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant.
- 297
- 298 Figure 2. Abnormal respiratory culture rates by COVID-19 status. Percentage of patients with
- abnormal respiratory cultures of those with any respiratory culture ordered. *** p < 0.001
- 300

301 Figure 3: Time from admission to respiratory culture positivity

A) Percentage of total COVID-19 or non-COVID patients with abnormal respiratory culture grouped by

time interval from admission to respiratory culture ordering comparing community acquired pneumonia

- 304 (CAP, <48hrs) to hospital-acquired (HAP) or ventilator-associated pneumonia (VAP). B) Percentage of
- total COVID-19 or non-COVID patients with abnormal respiratory culture who fit criteria for CAP, HAP

306 or VAP [8]. * p < 0.05, ** p < 0.01, *** p < 0.001

307

```
Figure 4: Bacterial species identified in abnormal respiratory cultures in COVID-19 positive vs.
negative patients. Percent of total patients in each category of COVID-19 status with the 10 most
common species for COVID-19 patients in descending order. * p < 0.05, ** p < 0.01, *** p < 0.001</li>
```

311

312 Supplementary Figure 1: Percentage of hospitalized patients with new positive SARS-CoV-2 PCR

tests per month during 2020. Based on the number of first-time positive SARS-CoV-2 PCR per month,

relative to total patients tested in that month. Tests recorded in the data base began on March 10, 2020.

315

316 Supplementary Figure 2: Rates of Respiratory Culture Ordering and Positivity in Intubated

Patients. A) Percentage of overall patients by COVID-19 status who are intubated. B) Percent of patients

318 with respiratory cultures ordered who are intubated or non-intubated by COVID-19 status. C) Percent of

319	patients with abnormal respiratory culture results who are intubated or non-intubated by COVID-19
320	status. D) Percentage of intubated, non-intubated or overall hospitalized patients who have respiratory
321	cultures ordered by COVID-19 status. E) Percent of intubated, non-intubated or overall hospitalized
322	patients with abnormal respiratory culture results out of the total number with cultures ordered by
323	COVID-19 status. For intubated patients, only those respiratory cultures collected more than 48 hours
324	after intubation were included. F) Percent of intubated or overall hospitalized patients with abnormal
325	respiratory cultures out of total patients by COVID-19 status. For intubated patients, only those
326	respiratory cultures collected more than 48 hours after intubation were included. * p < 0.05, ** p < 0.01,
327	*** p < 0.001
328	
329	Supplementary Figure 3: Rates of antibiotic resistance by category. Percentage of overall cultures with
330	each type of resistance. Penicillin class includes penicillin-like beta lactams: penicillin, oxacillin and
331	ampicillin; Cephalosporins include ceftriaxone and ceftazidime. $st \ p < 0.05$
227	
332	

333







Figure 2



Figure 3



В



Figure 4

